NewsBenzingaFate Therapeutics获得1500万美元CIRM拨款，推进第2阶段FT819试验在狼疮性肾炎中的应用 Fate Therapeutics获得1500万美元CIRM拨款，推进第2阶段FT819试验在狼疮性肾炎中的应用 Benzinga 2026.09.25 11:07 (GMT+0) Open on Benzinga Other news Why Is IREN Stock Surging Monday? Cleveland-Cliffs Q3 2026 Earnings Call Transcript On Sunday October 18, 2026 TeraWulf CEO Paul Prager Posted On X "$WULF is NOT a neocloud. $WULF IS an energy infrastructure company. We match long term investment grade energy supply with long term HPC/AI off-take. We finance our projects competitively... Cosmos Health Expects Q4 Sales Of ~$15M, Gross Profit Of ~$10.5M With Gross Margin Of ~70% Jefferies Maintains Hold on Kinetik Holdings, Lowers Price Target to $54 Stephens & Co. Maintains Equal-Weight on Regions Financial, Lowers Price Target to $30
On Sunday October 18, 2026 TeraWulf CEO Paul Prager Posted On X "$WULF is NOT a neocloud. $WULF IS an energy infrastructure company. We match long term investment grade energy supply with long term HPC/AI off-take. We finance our projects competitively...
